# CRISPR Therapeutics climbs 18% premarket after reporting completion of FDA advisory committee meeting for Exagamglogene autotemcel (EXA-cel) for sever...
**FDA Update**

**2023-11-01 08:40**

**https://www.ainvest.com/news/crispr-therapeutics-climbs-18-premarket-after-reporting-completion-of-fda-advisory-committee-meeting-for-exagamglogene-autotemcel-exa-cel-for-severe-sickle-cell-disease-23111000acf27fb06020278f/**

CRISPR Therapeutics climbs 18% premarket after reporting completion of FDA advisory committee meeting for Exagamglogene autotemcel (EXA-cel) for severe sickle cell disease